Consolidation ALK Tyrosine Kinase Inhibitors versus Durvalumab or Observation After Chemoradiation in Unresectable Stage III ALK+ Non-Small Cell Lung Cancer
Related Posts
Sasaki T, Cao Y, Sowerby JM, Higashioka K, Marks KE, Elahee M, Kamiya M, Dellaripa PF, Ainsworth RI, Taylor KE, Bottini N, Wolters P, Kim[...]
Plutzky J, Taub PR, Bhatt DL, Al Dhaybi O, Aroda VR, Basile JN, Bloch MJ, Budoff M, Busch RS, Buse JB, Cheung D, Christofides EA,[...]
Chin JH, Wyburd MK, Ayzenberg V, Bayet L, Bilgic B, Chen EM, Chen Y, Dineen Á, Fujita S, Liu J, Jun Y, Camacho MC, Zöllei[...]